Elaine Apperson
Pediatric Endocrinology · Greenville, SCNPI 1730267857
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 55.4% of the total. 2025 is the largest year on record at $26,040, 7.7 times the $3,360 reported in 2019.
Across 94 payments — averaging $489.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$25K
- Sanofi$11K
- Dexcom, Inc.$6K
- Xeris Pharmaceuticals, Inc.$1K
- Insulet Corporation$591
- Ipsen Biopharmaceuticals, Inc$323
- plus $1K from 19 others
Across 22 payments — averaging $4109.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$90K
What the payments were for
- Consulting fees$21,13646%
- Speaking & faculty fees$17,02437%
- Travel & lodging$4,2769%
- Food & beverage$3,1267%
- Education$4161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 18 | $25,449 |
| Sanofi | 6 | $10,908 |
| Dexcom, Inc. | 13 | $6,370 |
| Xeris Pharmaceuticals, Inc. | 1 | $1,035 |
| Insulet Corporation | 10 | $591 |
| Ipsen Biopharmaceuticals, Inc | 6 | $323 |
| BETA Bionics, Inc. | 2 | $309 |
| Medtronic(2 entities) | 2 | $232 |
| Ascendis Pharma Endocrinology Inc | 5 | $121 |
| Rhythm Pharmaceuticals, Inc. | 3 | $112 |
| AbbVie | 5 | $110 |
| Abbott | 5 | $105 |
| Tandem Diabetes Care, Inc. | 2 | $53 |
| Pfizer | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 2 | $24 |
| Novo Nordisk | 1 | $23 |
| Roche Diabetes Care, Inc. | 2 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$25,315
- DEXCOM CGM$3,205
- DEXCOM G6 TRANSMITTER$3,064
- GVOKE PFS$1,035
- iLet Bionic Pancreas$848
- Omnipod$331
How this compares
Too few pediatric endocrinology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Greenville
- Ryan DyessGreenville$2K
- Katherine LewisGreenville$2K
- Melissa GargantaGreenville$925
- James AmrheinGreenville$574
- Mary RoperGreenville$113
- Alison LunsfordColumbia$13K
- Tarina MendesSeneca$5K
- Deidre McSweeny-TysonFlorence$3K
- Lisa KnightColumbia$3K
- Whitney BrownColumbia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.